<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT01753830 on 2013_03_07: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT01753830">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT01753830">&#8593; Current version of this study</a></div><h1>View of NCT01753830 on
  2013_03_07</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT01753830</td>
</tr>
<tr>
<th>Updated:</th><td>2013_03_07</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>A Multi Center, Randomized, Double Blind, Saline Controlled Study of a Single Injection of Durolane&reg; Versus a Single Injection of Phosphate Buffered Saline (PBS) to Treat Pain Associated With Osteoarthritis of the Knee</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>The purpose of the study is to determine whether a single intra-articular injection of Durolane is superior to a single injection of PBS for the relief of joint pain in patients with osteoarthritis of the knee.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 3</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Double Blind (Subject, Outcomes Assessor)</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain score<br>Time Frame: Up to 30 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Outcome Measures in Rheumatology Clinical Trials (OMERACT)-Osteoarthritis Research Society International (OARSI) Response<br>Time Frame: Up to 30 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: WOMAC Physical Function score<br>Time Frame: Up to 30 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Knee injury and Osteoarthritis Outcome Score (KOOS) Quality of Life questionnaire<br>Time Frame: Up to 30 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Physical Global Evaluation<br>Time Frame: Up to 30 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Patient Global Evaluation<br>Time Frame: Up to 30 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Condition</th><td>
         Knee Osteoarthritis
      </td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: Durolane      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Experimental</div>
<p>Single intraarticular injection of Durolane</p>
</td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: PBS      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Placebo Comparator</div>
<p>Single intraarticular injection of PBS</p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Device: Durolane
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: Durolane</div>
<p></p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Device: PBS
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: PBS</div>
<p></p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Recruiting</td>
</tr>
<tr>
<th>Start date</th><td>
         2012-12
      </td>
</tr>
<tr>
<th>Primary completion date</th><td>
         2014-08
      
      (Anticipated)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion Criteria:<br> &nbsp;- Body Mass Index (BMI) &le; 35 kg/m2<br> &nbsp;- Symptomatic OA of the knee<br> &nbsp;- K L severity grade 1 or 2<br> &nbsp;- If bilateral OA, contralateral knee K L severity grade 0 or 1<br>
<br>Exclusion Criteria:<br> &nbsp;- Has clinically apparent tense effusion of the index knee<br> &nbsp;- Has had surgery on the symptomatic knee within the previous 12 months or arthroscopy in the index knee in the past 3 months<br> &nbsp;- Has any painful orthopedic disorders of the back or hip<br> &nbsp;- Has a joint disorder other than osteoarthritis in the index knee</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>40 Years</td>
</tr>
<tr>
<th>Maximum age</th><td>80 Years</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Q-Med AB</td>
</tr>
<tr>
<th>Organization study ID</th><td>35GA1203</td>
</tr>
<tr>
<th>Sponsor</th><td>
               Q-Med AB
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Food and Drug Administration
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
